UPDATE : Friday, May 29, 2020
HOME Special
[Pre-ASCO 2019] ABL Bio: ABL001- bispecific antibody with indications for anti-cancer therapy
  • By Lee Han-soo
  • Published 2019.05.21 12:47
  • Updated 2019.05.21 12:47
  • comments 0

The American Society of Clinical Oncology (ASCO) is one of the most eye-catching events in the global biotech industry as it is an opportunity to gauge the clinical success of pipeline for companies on the global stage. With the conference releasing its abstracts on Wednesday, Korea Biomedical Review has decided to introduce the key points of clinical outcomes and development strategies for Korean companies participating in ASCO in a series. -- Ed.

ABL Bio is set to become the first Korean company to present its poster session at ASCO 2019. The company will be giving an update on phase 1 clinical trial of its anti-drug candidate substance ABL001, a bispecific antibody with indications for anti-cancer and eye treatment.

The poster session will cover the safety and efficacy of the treatment in metastatic gastric cancer. In phase 1 clinical trial, the company enrolled 18 patients from November 2017 to February 2019.

In a classical 3+3 dose-escalation design, the company administered ABL001 at doses ranging from 0.3, 1, 2.5, 5, and 7.5 mg/kg biweekly. All patients were heavily pre-treated with at least three prior lines of chemotherapy, while those receiving 5 and 7.5 mg/kg all had either metastatic colorectal cancer or gastric cancer.

Of the five cohorts, the company observed no dose-limiting toxicity during dose escalation. Also, there was no maximum tolerated dose identified up to 7.5 mg/kg dose. The most common treatment-related adverse events (AEs) were hypertension, anorexia, general weakness, headache, and anemia.

ABL Bio plans to proceed with the 1b/2a phase by combining chemotherapy with anti-PD-1 antibody after completing the phase 1a trials

ABL-001, one of ABL Bio’s main pipelines, is a bispecific antibody that binds simultaneously to VEGF (vascular endothelial growth factor) and delta-like ligand 4 (DLL4), which play an essential role in the neovascularization process.

It has a high binding force to each antigen and has a structure that receives fewer structural interference when the antigen and antibody bind, which in turn, result in a high therapeutic effect. With such benefits, the company had signed a licensing-out agreement with TRIGR Therapeutics, a U.S. no research and development only (NRDO) company, for the substance.

ABL Bio is one of the fastest-growing companies in Korea. It has signed cooperation agreements with major local pharmaceutical companies, such as Yuhan, Dong-A ST and Handok, with its bispecific antibody technology.

The company plans to present its poster session on June 1, at Hall A of the McCormick Place in Chicago, Ill.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top